Synektik Group signed agreement with NUCEO from Latvia. This agreement pertains to extending a license to produce and distribute the Synektik Group’s radiopharmaceutical product utilized for PET (positron emission tomography) diagnostics under the commercial name of Glunektik (FDG, [18F] fluorodeoxyglucose). Under this agreement NUCLEO will be responsible for the production and distribution of Glunektik and for the related sales and marketing efforts in Latvia and Estonia.
The conclusion of this agreement is aligned with continuing the pursuit of the Synektik Group’s growth strategy calling for developing the production of radiopharmaceuticals and geographically expanding the markets for selling the products and services offered by the Group.
